OR WAIT 15 SECS
LAS VEGAS -- Skinvisible, Inc., through its wholly owned subsidiary Skinvisible Pharmaceuticals, Inc., announces that its patented antimicrobial hand sanitizer demonstrated a greater than 99 percent kill in laboratory studies against the Influenza A virus.
"Our studies performed at an FDA compliant laboratory confirm that our antimicrobial hand sanitizer product may help in preventing the spread of the Influenza A virus caused from hand to hand and surface to hand contact," says Skinvisible's CEO Terry Howlett.
Manufactured for and marketed by Michigan based Dermal Defense, Inc., this antimicrobial hand sanitizer incorporates Skinvisible's proprietary Invisicare polymer delivery system. Notable, proven advantages of the formulation include its ability to adhere to the skin, thereby forming a protective bond. It resists both wash-off and perspiration while holding the active ingredient Triclosan on the skin for extended periods of time.
The product, marketed as Dermal Defense, offers the added advantage of being alcohol-free. "Alcohol-based sanitizers typically provide instant protection but offer no long-term persistence," says Howlett. "These products require frequent reapplication, which is inconvenient for most people and because alcohol dries the skin, it can cause adverse reactions." Although proven to be effective on its own, Howlett notes that Dermal Defense is specifically designed to be a complementary adjunct to hand washing rather than a replacement.
The simplest way to avoid the flu is to stay away from crowds during an epidemic but this is easier said than done. "By incorporating Dermal Defense Antimicrobial Hand Sanitizer into a daily hygiene regime, one may reduce the risk of contracting Influenza A and other serious viral and bacterial infections," says Howlett. "It is especially recommended for people who regularly frequent schools, hospitals, athletic facilities, airports, shopping centers and other large public facilities."
Headquartered in Las Vegas, Nevada, Skinvisible, Inc. is focused on the development of innovative topical polymer-based delivery systems and related technologies incorporating its patent-pending formula/process for combining hydrophilic and hydrophobic polymers into stable water emulsions. Skinvisible's primary marketing and sales objectives are to license its technologies and/or sell its delivery systems to provide enhanced product performance for established brand manufacturers and providers of prescription, over-the-counter, cosmetic, and skincare products. In addition, Skinvisible formulates and manufactures products for private label customers.
Source: Skinvisible, Inc.